Table 4. Prognostic impact of CA9 and CD31 according to stroma density and activation.
| Marker expression (high vs low) | OS p-value | PFS p-value | LPFS p-value | DMFS p-value |
|---|---|---|---|---|
| CA9 | ||||
| Dense stroma | 0.715 | 0.517 | 0.775 | 0.860 |
| Moderate stroma | 0.913 | 0.617 | 0.879 | 0.756 |
| Loose Stroma | 0.658 | 0.985 | 0.667 | 0.889 |
| CD31 | ||||
| Dense stroma | 0.303 | 0.163 | 0.250 | 0.263 |
| Moderate stroma | 0.004 | 0.008 | 0.014 | 0.004 |
| Loose Stroma | 0.415 | 0.147 | 0.772 | 0.162 |
| CA9 | ||||
| Absent/low SMA | 0.420 | 0.542 | 0.283 | 0.791 |
| Moderate/strong SMA | 0.702 | 0.821 | 0.905 | 0.681 |
| CD31 | ||||
| Absent/low SMA | 0.702 | 0.338 | 0.462 | 0.241 |
| Moderate/strong SMA | 0.258 | 0.432 | 0.285 | 0.520 |
Abbreviations: OS, overall survival; PFS, progression-free survival; LFFS, local failure-free survival; DMFS, distant metastases-free survival; significant values have been marked with bold.